US Pharm. 2012;37(9):6.
Silver Spring, MD—The FDA has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease occurring in people with diabetes. In DME, fluid leaks into the macula and causes it to swell, which then blurs vision. All patients with diabetes have the risk of developing DME. Lucentis was previously approved to treat wet age-related macular degeneration and macular edema following retinal-vein occlusion. The drug, which is administered once monthly by a health care professional, is intended to be used together with good diabetic sugar control.
To comment on this article, contact rdavidson@uspharmacist.com.
